Acrivon Therapeutics, Inc. Common Stock cash flow to debt ratio of -2.35K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Acrivon Therapeutics, Inc. Common Stock's free cash flow has increased -4.53% from $-68.44M last year to $-65.33M, signaling increasing performance

Acrivon Therapeutics, Inc. Common Stock's debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability.

Acrivon Therapeutics, Inc. Common Stock's debt has increased relative to shareholder equity from 0.02 last year to 0.03 today, signaling weakened financials

Acrivon Therapeutics, Inc. Common Stock has a net cash position, so leverage is healthy.

Acrivon Therapeutics, Inc. Common Stock earns at least as much interest as it pays. Interest obligations are fully covered.

Acrivon Therapeutics, Inc. Common Stock has insufficient data to evaluate this check.

Acrivon Therapeutics, Inc. Common Stock's short-term assets of $120.44M exceed its short-term liabilities of $15.66M

Acrivon Therapeutics, Inc. Common Stock's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Acrivon Therapeutics, Inc. Common Stock's return on equity of -64.43%, is lower than 15.00%, indicating bad performance

Acrivon Therapeutics, Inc. Common Stock's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Acrivon Therapeutics, Inc. Common Stock has insufficient public price history to evaluate earnings stability.

Acrivon Therapeutics, Inc. Common Stock has negative free cash flow, indicating the company is burning cash rather than generating it

Acrivon Therapeutics, Inc. Common Stock has negative free cash flow, indicating cash burn

Acrivon Therapeutics, Inc. Common Stock's yearly earnings has increased -3.29% since last year from $-80.56M to $-77.91M, signaling increasing performance

Acrivon Therapeutics, Inc. Common Stock's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -84.09% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Acrivon Therapeutics, Inc. Common Stock has insufficient revenue history to calculate 3-year revenue CAGR.

Acrivon Therapeutics, Inc. Common Stock has insufficient public price history to evaluate revenue consistency.

Acrivon Therapeutics, Inc. Common Stock has insufficient public price history to evaluate ROE consistency.

Acrivon Therapeutics, Inc. Common Stock has insufficient data to evaluate this check.

Acrivon Therapeutics, Inc. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Acrivon Therapeutics, Inc. Common Stock is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Acrivon Therapeutics, Inc. Common Stock has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Acrivon Therapeutics, Inc. Common Stock has insufficient data to evaluate this check.

Acrivon Therapeutics, Inc. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Acrivon Therapeutics, Inc. Common Stock has a price-to-book ratio of 0.71x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Acrivon Therapeutics, Inc. Common Stock has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue